Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Bladder Cancer

Free Subscription 15.09.2025 1 Acad Radiol 1 Appl Biochem Biotechnol 1 Bioelectrochemistry 1 Biomed Eng Lett 1 Biomed Rep 2 BJU Int 2 Bladder (San Franc) 1 Colloids Surf A Physicochem Eng Asp 1 Cureus 1 Curr Med Imaging 1 Curr Opin Urol 1 Elife 1 Eur J Med Chem 1 Eur J Surg Oncol 3 Front Oncol 1 Front Pharmacol 2 Harefuah 1 Health Sci Rep 1 Int J Cancer 1 Int J Nanomedicine 2 Int J Surg 2 J Clin Oncol 1 J Egypt Natl Canc Inst 1 J Urol 1 JCO Clin Cancer Inform 1 Med Pr 1 Mol Carcinog 1 Mol Cell Probes 1 Mol Immunol 1 Nat Commun 1 Nat Rev Urol 1 Oncol Res 1 Pediatr Surg Int 1 Protein Pept Lett 1 Ther Adv Urol 1 Toxicol Lett 1 Transl Oncol 1 Urol J 10 Urol Oncol 1 Urologia 2 Urologiia 1 Urology 1 Vet J 1 World J Urol 1 Zhong Nan Da Xue Xue Bao Yi Xue Ban 1 Zhonghua Bing Li Xue Za Zhi

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Acad Radiol

1. WANG Z, Shi H, Wang Q, Huang Y, et al
   AI-driven and Traditional Radiomic Model for Predicting Muscle Invasion in Bladder Cancer via Multi-parametric Imaging: A Systematic Review and Meta-analysis.
   Acad Radiol. 2025 Sep 5:S1076-6332(25)00806-2. doi: 10.1016/j.acra.2025.
   PubMed         Abstract available
   
   

   
   Appl Biochem Biotechnol

2. DAI H, Zhang Y, Yu S, Feng Y, et al
   miR-19b-3p Affects the Proliferation and Apoptosis of Bladder Cancer Cells by Regulating the Stability of lncRNA SNHG20.
   Appl Biochem Biotechnol. 2025 Sep 6. doi: 10.1007/s12010-025-05370.
   PubMed         Abstract available
   
   

   
   Bioelectrochemistry

3. JUNLAPAK N, Khumngern S, Nontipichet N, Kangkamano T, et al
   A label-free electrochemical immunosensor for bladder tumor marker NMP22 using AuNPs@OMC and Thi@Gr-COOH nanocomposites.
   Bioelectrochemistry. 2026;167:109074.
   PubMed         Abstract available
   
   

   
   Biomed Eng Lett

4. NAM KC, Park BJ
   Antibacterial and anticancer activity of multifunctional iron-based magnetic nanoparticles against urinary tract infection and cystitis-related bacterial strains and bladder cancer cells.
   Biomed Eng Lett. 2025;15:903-915.
   PubMed         Abstract available
   
   

   
   Biomed Rep

5. DONG J, Guo Y, Ji T, Guan H, et al
   Puerariae radix flavones induce apoptosis in bladder cancer T24 cells via the FAS/TNFR1 pathway: A potential therapeutic candidate.
   Biomed Rep. 2025;23:170.
   PubMed         Abstract available
   
   

   
   BJU Int

6. FAZILI A, Jazayeri SB, Rose KM, Guske C, et al
   Cisplatin-ineligible patients with muscle-invasive bladder cancer demonstrate poor long-term survival following immediate radical cystectomy.
   BJU Int. 2025 Sep 11. doi: 10.1111/bju.16895.
   PubMed         Abstract available
   
   
7. CLEMENTS MB, Pekala KR, Tin AL, Sjoberg DD, et al
   Prospective health-related quality of life in women undergoing radical cystectomy and urinary diversion.
   BJU Int. 2025;136:728-737.
   PubMed         Abstract available
   
   

   
   Bladder (San Franc)

8. ZHONG H, He W, Mo M, Tong S, et al
   Neoadjuvant therapy plus thulium laser transurethral bladder tumor resection for muscle-invasive bladder cancer.
   Bladder (San Franc). 2025;12:e21200053.
   PubMed         Abstract available
   
   
9. LIU Y, Liu L, Yao Z, Hou Y, et al
   Applications and future prospects of laser technologies in the treatment of non-muscle invasive bladder cancer.
   Bladder (San Franc). 2025;12:e21200050.
   PubMed         Abstract available
   
   

   
   Colloids Surf A Physicochem Eng Asp

10. HUANG W, Chao F, Hsu JC, Sun X, et al
    Noninvasive ImmunoPET imaging of PD-L1 expression in non-small cell lung cancer and bladder cancer using [(89)Zr]Zr-DFO-Durvalumab.
    Colloids Surf A Physicochem Eng Asp. 2025;723:137332.
    PubMed         Abstract available
    
    

    
    Cureus

11. AKINTELURE D, Tawose P, Akintelure S, Agada R, et al
    Tropomyosin Isoforms as Biomarkers for Urothelial Bladder Cancer: Promise and Challenges.
    Cureus. 2025;17:e89801.
    PubMed         Abstract available
    
    

    
    Curr Med Imaging

12. CAO T, Li N, Guo C, Zhang H, et al
    CT-based Radiomics of Intratumoral and Peritumoral Regions to Predict the Recurrence Risk in Patients with Non-muscle-invasive Bladder Cancer within Two Years after TURBT.
    Curr Med Imaging. 2025 May 26. doi: 10.2174/0115734056350444250418075406.
    PubMed         Abstract available
    
    

    
    Curr Opin Urol

13. KITAMURA H, Nishiyama N
    Oncolytic virus therapy for nonmuscle-invasive bladder cancer: current status and future directions.
    Curr Opin Urol. 2025 Sep 8. doi: 10.1097/MOU.0000000000001331.
    PubMed         Abstract available
    
    

    
    Elife

14. LIU L, Liu Z, Fan L, Yao Z, et al
    An evaluation of the tumor microenvironment through CALR, IL1R1, IFNB1, and IFNG to assess prognosis and immunotherapy response in bladder cancer patients.
    Elife. 2025;13:RP95326.
    PubMed         Abstract available
    
    

    
    Eur J Med Chem

15. YANG X, Wang L, Lin P, Ning Y, et al
    Corrigendum to "Discovery of Artesunate (ARS) PROTACs as GPX4 protein degraders for the treatment of bladder cancer" [Eur. J. Med. Chem. 293 (2025) 117710].
    Eur J Med Chem. 2025 Sep 10:118140. doi: 10.1016/j.ejmech.2025.118140.
    PubMed        
    
    

    
    Eur J Surg Oncol

16. BERTOLO R, Cianflone F, Pettenuzzo G, Costantino S, et al
    The impact of early versus delayed ureteral ligation on renal function after robot-assisted radical cystectomy.
    Eur J Surg Oncol. 2025;51:110213.
    PubMed         Abstract available
    
    

    
    Front Oncol

17. DA Y, Lu Z, Zhu Z, Tai H, et al
    A high stroma-tumor ratio is associated with an immunosuppressive tumor microenvironment and a poor prognosis in bladder cancer.
    Front Oncol. 2025;15:1604609.
    PubMed         Abstract available
    
    
18. HUANG J, Zhou C, Yu Z, Song Z, et al
    A novel prognostic biomarker DUSP6 promote the malignant progression of bladder cancer through mTOR mediated mitophagy.
    Front Oncol. 2025;15:1603069.
    PubMed         Abstract available
    
    
19. ZHOU Q, Ma L, Yu Y, Zhang C, et al
    Development of a radiomics and clinical feature-based nomogram for preoperative prediction of pathological grade in bladder cancer.
    Front Oncol. 2025;15:1661979.
    PubMed         Abstract available
    
    

    
    Front Pharmacol

20. LIU X, Ding G, Liu Y, Yan X, et al
    Epigenetic regulation of bladder cancer in the context of aging.
    Front Pharmacol. 2025;16:1617452.
    PubMed         Abstract available
    
    

    
    Harefuah

21. BENZEKRY I, Klein I, Pavlov A, Dekel Y, et al
    [MASSIVE TUMOR INSIDE A GIANT BLADDER DIVERTICULUM].
    Harefuah. 2025;164:529-531.
    PubMed         Abstract available
    
    
22. FAZAA N, Shashar R, Malshy K, Amiel G, et al
    [INNOVATIONS IN THERAPIES FOR BACILLUS CALMETTE-GUERIN (BCG) FAILURE NON-MUSCLE INVASIVE PATIENTS].
    Harefuah. 2025;164:524-528.
    PubMed         Abstract available
    
    

    
    Health Sci Rep

23. CHE K, Qian D, Cui S, Xie F, et al
    Dissecting Causal Relationships Between Gut Microbiota, Plasma Metabolites and Bladder Cancer: A Two-Step Mendelian Randomization Study.
    Health Sci Rep. 2025;8:e71206.
    PubMed         Abstract available
    
    

    
    Int J Cancer

24. PILALA KM, Koroneou S, Papadimitriou MA, Panoutsopoulou K, et al
    Loss of METTL3 m6A methyltransferase results in short-term progression and poor treatment outcome of bladder cancer patients.
    Int J Cancer. 2025 Sep 9. doi: 10.1002/ijc.70147.
    PubMed         Abstract available
    
    

    
    Int J Nanomedicine

25. LIU Y, Lv H, Chen Y, Ye S, et al
    Cu(2)(OH)PO(4)@PAA Nanoparticles for Highly Effective Combination of Chemodynamic, Photodynamic and Photothermal Therapies Against Bladder Cancer.
    Int J Nanomedicine. 2025;20:10701-10719.
    PubMed         Abstract available
    
    

    
    Int J Surg

26. XIE H, Yi X, Wei W
    A commentary on "A nomogram for predicting lymph node metastases in nonmetastatic muscle-invasive bladder cancer: a SEER-based investigation".
    Int J Surg. 2025 Sep 10. doi: 10.1097/JS9.0000000000003346.
    PubMed        
    
    
27. ZHANG D, Ren J, Ye J, Wu R, et al
    Bladder cancer risk factors: a comprehensive umbrella review of meta-analyses.
    Int J Surg. 2025 Sep 10. doi: 10.1097/JS9.0000000000003371.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

28. NECCHI A, Galsky MD, Dizman N, Aggen DH, et al
    End Points for the Next-Generation Bladder-Sparing Perioperative Trials for Patients With Muscle-Invasive Bladder Cancer.
    J Clin Oncol. 2025 Sep 11:JCO2501608. doi: 10.1200/JCO-25-01608.
    PubMed         Abstract available
    
    
29. DANESHMAND S, Van der Heijden MS, Jacob JM, Guerrero-Ramos F, et al
    Erratum: TAR-200 for Bacillus Calmette-Guerin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study.
    J Clin Oncol. 2025 Sep 9:JCO2502053. doi: 10.1200/JCO-25-02053.
    PubMed        
    
    

    
    J Egypt Natl Canc Inst

30. NASSAR O, Farahat IG
    Prostate sparing radical cystectomy and neobladder: institutional long-standing qualified consideration.
    J Egypt Natl Canc Inst. 2025;37:58.
    PubMed         Abstract available
    
    

    
    J Urol

31. GUTIERREZ J, Ayub A, Piva SE, Shirk JD, et al
    IP11-07 A 3D Tumor Map for the Surgical Management of Bladder Cancer: Feasibility and Preliminary Analysis: Erratum.
    J Urol. 2025;214:458.
    PubMed        
    
    

    
    JCO Clin Cancer Inform

32. LU K, Chao L, Wang J, Wang X, et al
    Erratum: Risk Score Model of Aging-Related Genes for Bladder Cancer and Its Application in Clinical Prognosis.
    JCO Clin Cancer Inform. 2025;9:e2500251.
    PubMed        
    
    

    
    Med Pr

33. MICHALIK T, Wrobel M, Fedorowicz S, Michalik K, et al
    [Bladder cancer in geriatric patients].
    Med Pr. 2025 Sep 1:209113. doi: 10.13075/mp.5893.01621.
    PubMed         Abstract available
    
    

    
    Mol Carcinog

34. ZHOU L, Yu G, Zheng Z, Xu B, et al
    IGHA1 and IGHG1 Expression Panel Predicts Anti-PD-L1 Response in Muscle-Invasive Bladder Cancer.
    Mol Carcinog. 2025 Sep 8. doi: 10.1002/mc.70033.
    PubMed         Abstract available
    
    

    
    Mol Cell Probes

35. HAIDER CG, Wang Q, Wang G, Wang Y, et al
    Copy number variations in urine cell-free DNA from bladder neoplasm patients.
    Mol Cell Probes. 2025;83:102044.
    PubMed         Abstract available
    
    

    
    Mol Immunol

36. WANG K, Gu Q, Xue C, Shi J, et al
    MAP30 inhibits proliferation and metastasis of bladder cancer by increasing EGR1 expression and promoting the transcriptional activation of DUSP1.
    Mol Immunol. 2025;187:48-60.
    PubMed         Abstract available
    
    

    
    Nat Commun

37. CHANG K, Delavan HM, Yip E, Kasap C, et al
    Modulating the PPARgamma pathway upregulates NECTIN4 and enhances chimeric antigen receptor (CAR) T cell therapy in bladder cancer.
    Nat Commun. 2025;16:8215.
    PubMed         Abstract available
    
    

    
    Nat Rev Urol

38. WEN L, Miyagi H, Spiess PE, Yu A, et al
    Low-grade non-muscle-invasive bladder cancer: molecular landscape, treatment strategies and emerging therapies.
    Nat Rev Urol. 2025 Sep 10. doi: 10.1038/s41585-025-01072.
    PubMed         Abstract available
    
    

    
    Oncol Res

39. PENG L, Cai T, Xu P, Chen C, et al
    Integrating Spatial Multi-Omics and Machine Learning to Unravel the Role of PANoptosis in Bladder Cancer Prognosis and Immunotherapy Response.
    Oncol Res. 2025;33:2463-2489.
    PubMed         Abstract available
    
    

    
    Pediatr Surg Int

40. BROOKS G, Ghidini F, Virgone C, De Corti F, et al
    Long-term complications in patients with bladder-prostate rhabdomyosarcoma treated with brachytherapy: a systematic review.
    Pediatr Surg Int. 2025;41:290.
    PubMed         Abstract available
    
    

    
    Protein Pept Lett

41. FANG Q, You C, Xiao X, Liu Y, et al
    Mevalonate Metabolic Reprogramming Drives Cisplatin Resistance in Bladder Cancer: Mechanisms and Therapeutic Targeting.
    Protein Pept Lett. 2025 Sep 3. doi: 10.2174/0109298665403178250806111943.
    PubMed         Abstract available
    
    

    
    Ther Adv Urol

42. LI J, Song Y, Chen R, Gao H, et al
    Evaluating repeat transurethral resection after en bloc resection for non-muscle invasive bladder cancer.
    Ther Adv Urol. 2025;17:17562872251367555.
    PubMed         Abstract available
    
    

    
    Toxicol Lett

43. CONG B, Liu H, Sun M, Hu D, et al
    Bisphenol A exposure promotes proliferation and invasion capabilities of bladder cancer cells: Insights from gene expression and pathway analysis.
    Toxicol Lett. 2025 Sep 5:S0378-4274(25)01577.
    PubMed         Abstract available
    
    

    
    Transl Oncol

44. SAKATANI T, Tanaka S, Murakami K, Aguilar F, et al
    Development and analytical validation of a multiplex diagnostic qPCR-array as a potential application in predicting the response to neoadjuvant chemotherapy in muscle invasive bladder cancer.
    Transl Oncol. 2025;61:102528.
    PubMed         Abstract available
    
    

    
    Urol J

45. XU X, Liang Z, Feng Y, Qi H, et al
    Preliminary Functional Outcome Following Robotic Intracorporeal Orthotopic Ileal Neobladder with Integrated Pelvic Fascial Structure-Sparing in Males with Bladder Cancer.
    Urol J. 2025 Sep 6. doi: 10.22037/uj.v22i.8450.
    PubMed         Abstract available
    
    

    
    Urol Oncol

46. CHEN F, Simsir A, Cheng L
    Molecular testing in urinary cytology specimens: Current status and future directions.
    Urol Oncol. 2025;43:565-578.
    PubMed         Abstract available
    
    
47. GAZZONI G, Michelon I, Vilbert M, Oliveira JP, et al
    Enfortumab vedotin-related skin toxicities in patients with urothelial carcinoma: A systematic review and meta-analysis.
    Urol Oncol. 2025;43:595.
    PubMed         Abstract available
    
    
48. HART LJ, Barker K, Ruzdija D, Bertolo A, et al
    Tumor profiling of advanced urothelial carcinoma: Comparative analysis based on social determinants of health.
    Urol Oncol. 2025;43:596.
    PubMed         Abstract available
    
    
49. MOON HH, Aragon-Ching JB, Thompson A, Abraham A, et al
    Early real-world utilization of avelumab switch maintenance among patients with advanced urothelial carcinoma without progression following treatment with first-line platinum-based chemotherapy.
    Urol Oncol. 2025;43:594.
    PubMed         Abstract available
    
    
50. CHOW RD, Mamtani R
    Assessment of synergistic vs. independent drug activity for enfortumab vedotin and pembrolizumab in untreated advanced urothelial carcinoma.
    Urol Oncol. 2025;43:597.
    PubMed         Abstract available
    
    
51. HOSSAIN MN, Das D, Mostofa MA, Hosen MI, et al
    Targeted hotspot profiling reveals a functionally relevant mutation in bladder cancer.
    Urol Oncol. 2025 Sep 9:S1078-1439(25)00317-5. doi: 10.1016/j.urolonc.2025.
    PubMed         Abstract available
    
    
52. ROBERSON DS, McLeay MT 2nd, Henning G, Morales-Martinez G, et al
    The impact of prophylactic incisional negative pressure wound therapy on surgical site infection following open radical cystectomy.
    Urol Oncol. 2025;43:586-593.
    PubMed         Abstract available
    
    
53. RODRIGUEZ PENARANDA N, Di Bello F, Marmiroli A, Falkenbach F, et al
    Cancer-specific mortality in secondary bladder cancer after nephroureterectomy for upper tract urothelial carcinoma.
    Urol Oncol. 2025 Sep 5:S1078-1439(25)00312-6. doi: 10.1016/j.urolonc.2025.
    PubMed         Abstract available
    
    
54. PETRELLI F, Dottorini L, Ghidini A, Ceresoli F, et al
    Comparison of adjuvant and neoadjuvant therapies for muscle invasive bladder cancer: A network meta-analysis.
    Urol Oncol. 2025 Sep 10:S1078-1439(25)00333.
    PubMed         Abstract available
    
    
55. BAI K, Pingle SR, Chung R, Joffe BI, et al
    Revisiting BCG: The potential of rescue BCG therapy for BCG-unresponsive non-muscle-invasive bladder cancer.
    Urol Oncol. 2025 Sep 6:S1078-1439(25)00313-8. doi: 10.1016/j.urolonc.2025.
    PubMed         Abstract available
    
    

    
    Urologia

56. CHAVES MEDINA MJ, Villada Florez D, Castaneda Millan DA, Garcia-Perdomo HA, et al
    Using epigenetics as an alternative treatment for bladder cancer: A literature review.
    Urologia. 2025 Sep 10:3915603251372377. doi: 10.1177/03915603251372377.
    PubMed         Abstract available
    
    

    
    Urologiia

57. DMITRIEVA T A, Popov A Y, Gritskevich A A, Makarov V A, et al
    [Review of current methods of diagnosis and treatment of locally advanced urothelial bladder cancer].
    Urologiia. 2025;:96-102.
    PubMed         Abstract available
    
    
58. PERLIN D V, Shmanev A O, Shamkhalov Sh N, Zipunnikov V P, et al
    [Recurrence of urothelial bladder cancer in the upper urinary tract after radical cystectomy: is there prevention and what are the treatment options?].
    Urologiia. 2025;:59-63.
    PubMed         Abstract available
    
    

    
    Urology

59. WESTERMAN ME, Delacroix SE Jr
    Editorial Comment: Muscle-Invasive Bladder Cancer Treatment Selection in an Emerging Treatment Era: A Patient Preference Study.
    Urology. 2025 Sep 4:S0090-4295(25)00838-6. doi: 10.1016/j.urology.2025.
    PubMed        
    
    

    
    Vet J

60. HAYASHI A, Maeda S, Yamazaki A, Nakamura T, et al
    Urinary lipid production in dogs with urothelial carcinoma.
    Vet J. 2025;313:106373.
    PubMed         Abstract available
    
    

    
    World J Urol

61. MASTROIANNI R, Iannuzzi A, Ragusa A, Tuderti G, et al
    Impact of pad wetness on health-related quality of life after radical cystectomy and orthotopic neobladder.
    World J Urol. 2025;43:548.
    PubMed         Abstract available
    
    

    
    Zhong Nan Da Xue Xue Bao Yi Xue Ban

62. WANG L, Ren D, Cai Z, Hu W, et al
    O-GlcNAcylated YTHDF2 promotes bladder cancer progression by regulating the tumor suppressor gene PER1 via m(6)A modification.
    Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2025;50:827-839.
    PubMed         Abstract available
    
    

    
    Zhonghua Bing Li Xue Za Zhi

63. XIE JL, Li XJ, Zhang YL, Zheng YY, et al
    [Primary lymphomas in urinary bladder: a clinicopathological analysis of 23 cases].
    Zhonghua Bing Li Xue Za Zhi. 2025;54:925-931.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge.